Real-World data reveals Luspatercept's impact on MDS patients
NCT ID NCT06851065
First seen Feb 18, 2026 · Last updated May 24, 2026 · Updated 22 times
Summary
This study looked back at medical records of 418 adults with lower-risk myelodysplastic syndromes (MDS) who had not previously received certain anemia treatments. Researchers examined how doctors prescribed luspatercept, how long patients stayed on it, and what outcomes occurred, including blood transfusion needs and disease progression. The goal was to understand real-world effectiveness, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
RTI Health Solutions
Raleigh, North Carolina, 27709-2194, United States
Conditions
Explore the condition pages connected to this study.